Surgery Partners, Inc. Price & Performance (SGRY)

Benchmark analysts have reaffirmed their $35 price target on Surgery Partners, calling the company undervalued as it trades near its 52-week low. With Q1 results due May 12, analysts believe conservative guidance is justified amid economic uncertainty. Revenue rose 13.5% year-over-year, but integration costs may affect margins in early 2025.12

Bain Capital, already Surgery Partners' largest shareholder, has submitted a non-binding proposal to acquire the remaining shares and privatize the company. The deal, requiring approval by independent directors, has raised concerns about growing private equity influence in the ambulatory surgery center sector and could reshape industry dynamics.32

Surgery Partners maintains a consensus 'Moderate Buy' rating from analysts, with price targets around $35. Recent insider sales, including those by CFO David Doherty and insider Marissa Brittenham, have drawn attention. Despite a negative net margin, the company posted positive earnings last quarter, slightly surpassing expectations.45